Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Biologics Market Briefing 2017: Market is Expected to Reach Around $291 Billion in 2020 - Research and Markets

Research and Markets
Posted on: 03 Jan 18

The "Biologics Market Global Briefing 2017" report has been added to Research and Markets' offering.

The global biologics market is expected to reach around $291 billion in 2020. This can be attributed to the increasing evidence of positive responses to treatment with biologics, availability of advanced diagnostics increasing the treatment population, and rising government initiatives for the research and development of biologics globally thereby increasing the acceptance of the products in the market and increasing amount of patient population using the biologics.

The biologics industry comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.

Demand For Biologics In The Treatment Of Complex Diseases - Biologics are being widely used to provide effective treatment for many complex diseases such as rheumatoid arthritis, psoriasis, Crohn's disease that have limited treatment options. There has been a significant advancement for the treatment of Rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs.

The key biologics used for the treatment of Rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan). Key biologics used to treat psoriasis include Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade), Secukinumab ( Cosentyx). Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab), Tysabri (natalizumab) are biologics that are used to treat Crohn's disease.

Scope:

  • Markets Covered: Therapeutic Proteins, Monoclonal Antibodies (MAbS), Vaccines.
  • Time Series: Five years historic and forecast.
  • Data: Market value in $ billions.
  • Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

  • Amgen
  • AbbVie
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Pfizer
  • Eli Lilly
  • F. Hoffmann-La Roche Ltd
  • Merck & Co.
  • GlaxosmithKline
  • Novo Nordisk

For more information about this report visit https://www.researchandmarkets.com/research/wk723m/global_biologics?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180103005987/en/

Business Wire
www.businesswire.com

Last updated on: 03/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.